Dr. Meyerhardt is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
450 Brookline Ave
Dana-Farber Cancer Inst
Boston, MA 02215Phone+1 617-632-6855Fax+1 617-632-5370
Summary
- Dr. Jeffrey Meyerhardt is an oncologist in Boston, MA and is affiliated with Dana-Farber Cancer Institute and Brigham and Women's Hospital. He received his medical degree from Yale University School of Medicine and has been in practice 20 years. He specializes in gastrointestinal oncology.
Education & Training
- Brigham and Women's Hospital/Massachusetts General Hospital/Dana-Farber Cancer InstituteFellowship, Hematology and Medical Oncology, 2000 - 2002
- Beth Israel Deaconess Medical CenterResidency, Internal Medicine, 1997 - 2000
- Yale School of MedicineClass of 1997
Certifications & Licensure
- MA State Medical License 1999 - 2026
- NH State Medical License 2024 - 2024
- RI State Medical License 2020 - 2020
- American Board of Internal Medicine Medical Oncology
Awards, Honors, & Recognition
- Regional Top Doctor Castle Connolly, 2014
- Whos Who in Medicine and Healthcare Marquis Whos Who
Clinical Trials
- Study of Bevacizumab, Erlotinib, FOLFOX for Patients With Untreated Metastatic Colorectal Cancer Start of enrollment: 2005 Jan 01
- Gemcitabine and Cisplatin for Gallbladder and Biliary Tract Cancer Start of enrollment: 2002 Jul 01
- Tarceva, Capecitabine and Oxaliplatin for Metastatic Colorectal Cancer Start of enrollment: 2003 Mar 01
- Join now to see all
Publications & Presentations
PubMed
- Experience and Needs of Patients With Young-Onset Colorectal Cancer and Their Caregivers: A Qualitative Study.Kalen M Fletcher, Anna Revette, Andrea Enzinger, Leah Biller, Katelyn MacDougall
JCO Oncology Practice. 2024-12-01 - Inflammation, physical activity, and disease-free survival in stage III colon cancer: Cancer and Leukemia Group B-Southwest Oncology Group 80702 (Alliance).Justin C Brown, Chao Ma, Qian Shi, Felix Couture, Philip Kuebler
Journal of the National Cancer Institute. 2024-12-01 - 1 citationsAn Empirical Dietary Pattern Associated With the Gut Microbial Features in Relation to Colorectal Cancer Risk.Kai Wang, Chun-Han Lo, Raaj S Mehta, Long H Nguyen, Yiqing Wang
Gastroenterology. 2024-12-01
Journal Articles
- Aspirin Use and Risk of Colorectal Cancer Among Older AdultsLong H Nguyen, Kimmie Ng, Jeffrey A Meyerhardt, Andrew T Chan, JAMA Oncology
- Association of Diet Quality with Survival Among People with Metastatic Colorectal Cancer in the Cancer and Leukemia B and Southwest Oncology Group 80405 TrialKimmie Ng, Chloe Atreya, Howard S Hochster, James N Atkins, Richard M Goldberg, Charles D Blanke, Jeffrey A Meyerhardt, JAMA Network Open
- Association of Coffee Intake with Survival in Patients with Advanced or Metastatic Colorectal CancerI-Wen Chang, Charles D Blanke, Alan P Venook, Richard M Goldberg, Jeffrey A Meyerhardt, Kimmie Ng, JAMA Oncology
Lectures
- Lessons From IDEA: Duration in Stage II and III Colon CancerASCO Annual Meeting 2019 - Chicago, IL - 6/1/2019
Other
- The roles of diet, physical activity, and body weight in cancer survivorshipMeyerhardt JA, Ligibel J
http://www.uptodate.com/contents/the-roles-of-diet-physical-activity-and-body-weight-in-cancer-survi
UpToDate, Wolters Kluwer Health - 2013-04-09 - Cancer of the appendix and pseudomyxoma peritoneiMeyerhardt JA, Swanson R
http://www.uptodate.com/contents/cancer-of-the-appendix-and-pseudomyxoma-peritonei
UpToDate, Wolters Kluwer Health - 2013-03-22 - Infusion reactions to therapeutic monoclonal antibodies used for cancer therapyMeyerhardt JA, LaCasce AS, Burstein H, Castells MC
http://www.uptodate.com/contents/infusion-reactions-to-therapeutic-monoclonal-antibodies-used-for-ca
UpToDate, Wolters Kluwer Health - 2013-03-22
Authored Content
- Vitamin D Status After Colorectal Cancer Diagnosis and Patient Survival According to Immune Response to TumourOctober 2018
Press Mentions
- Dana-Farber Cancer Institute Faculty Among World's Most Highly Cited ResearchersNovember 19th, 2024
- Chronic Stress Speeds Colorectal Cancer’s Spread Dramatically, Study IndicatesOctober 12th, 2024
- Comprehensive cancer research from Dana-Farber to lead ESMO Congress 2024September 11th, 2024
- Join now to see all
Grant Support
- Exercise And Metformin To Impact Hyperinsulinemia In Colorectal Cancer SurvivorsNational Cancer Institute2011
- The Influence Of Diet And Lifestyle On Patients With Advanced Colorectal CancerNational Cancer Institute2010–2011
- The Role Of Pi3-Kinase Signaling Pathway In Defining Sensitivity And ResistanceNational Cancer Institute2007–2011
- Predictors Of Outcome In Colorectal CancerNational Cancer Institute2003–2007
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: